Science 37, a developer of the decentralized clinical trial operating system, went public via a SPAC merger with LifeSci Acquisition II, a special purposes acquisition company, in a $1bn deal. That deal comes with $200m through an upsized PIPE from a bunch of investors, including Redmile Group, BlackRock, Casdin Capital, dRx Capital, LifeSci Venture Partners, Lux Capital, Mubadala Capital, Perceptive Advisors, PPD, Pura Vida Investments, RS Investments, RTW Investments, Samsara BioCapital, and Surveyor Capital. "Science 37’s extraordinary differentiation based on its technology platform and specialized networks represents the future of clinical trial operations. As a leader and innovator in agile clinical trials, Science 37 has the opportunity to transform the industry and impact positive change in millions of people's lives. We are proud to partner with David and his talented team as Science 37 begins its next chapter as a public company," Andrew McDonald, LifeSci Acquisition II CEO.